PET studies and motor complications in Parkinson's disease.
Parkinson's disease (PD) patients with motor complications show a greater reduction in putamen [18F]dopa uptake on positron emission tomography (PET) compared with sustained responders to L-dopa, although individual ranges overlap considerably. This implies that, although loss of putamen dopamine storage predisposes motor complications in PD, it cannot be the only factor determining timing of onset. Additional PET studies suggest that loss of striatal dopamine storage capacity along with pulsatile exposure to exogenous L-dopa results in pathologically raised synaptic dopamine levels and deranged basal ganglia opioid transmission.This, rather than altered dopamine receptor binding, then causes inappropriate overactivity of basal ganglia-frontal projections, resulting in breakthrough involuntary movements.
Brooks
D J
DJ
MRC Clinical Sciences Centre, Imperial College School of Medicine, Hammersmith Hospital, London, UK.
D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism*; D003342:Corpus Striatum / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives; D004409:Dyskinesia, Drug-Induced / Q000000981:diagnostic imaging / Q000378:metabolism*; D005462:Fluorine Radioisotopes; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects*; D009434:Neural Pathways; D018847:Opioid Peptides / Q000378:metabolism; D010300:Parkinson Disease / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy; D020551:Pulse Therapy, Drug / Q000009:adverse effects*; D011699:Putamen / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism; D014055:Tomography, Emission-Computed
D000978:Antiparkinson Agents; D005462:Fluorine Radioisotopes; D018847:Opioid Peptides; D011957:Receptors, Opioid; C043437:fluorodopa F 18; D007980:Levodopa; D004295:Dihydroxyphenylalanine